Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 195

1.

Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumours.

Ebata T, Shimizu T, Fujiwara Y, Tamura K, Kondo S, Iwasa S, Yonemori K, Shimomura A, Kitano S, Koyama T, Sato N, Nakai K, Inatani M, Yamamoto N.

Invest New Drugs. 2019 May 24. doi: 10.1007/s10637-019-00787-3. [Epub ahead of print]

PMID:
31124055
2.

Bone marrow examination in patients with Ewing sarcoma/peripheral primitive neuroectodermal tumor without metastasis based on 18F-fluorodeoxyglucose positron emission tomography/computed tomography.

Inagaki C, Shimoi T, Sumiyoshi Okuma H, Kawachi A, Sudo K, Shimomura A, Noguchi E, Kodaira M, Yunokawa M, Yonemori K, Shimizu C, Arakawa A, Ogawa C, Yoshida A, Fujiwara Y, Tamura K.

Med Oncol. 2019 May 18;36(7):58. doi: 10.1007/s12032-019-1279-8.

PMID:
31104192
3.

Effects of bowel preparation on the human gut microbiome and metabolome.

Nagata N, Tohya M, Fukuda S, Suda W, Nishijima S, Takeuchi F, Ohsugi M, Tsujimoto T, Nakamura T, Shimomura A, Yanagisawa N, Hisada Y, Watanabe K, Imbe K, Akiyama J, Mizokami M, Miyoshi-Akiyama T, Uemura N, Hattori M.

Sci Rep. 2019 Mar 11;9(1):4042. doi: 10.1038/s41598-019-40182-9.

4.

Next endoscopic approach for acute lower gastrointestinal bleeding without an identified source on colonoscopy: upper or capsule endoscopy?

Aoki T, Nagata N, Yamada A, Shimbo T, Matsushita Y, Shimomura A, Kobayashi S, Moriyasu S, Niikura R, Sakurai T, Hirata Y, Akiyama J, Uemura N, Koike K.

Endosc Int Open. 2019 Mar;7(3):E337-E346. doi: 10.1055/a-0824-6647. Epub 2019 Feb 28.

5.

Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: A hospital-based study.

Sunami K, Ichikawa H, Kubo T, Kato M, Fujiwara Y, Shimomura A, Koyama T, Kakishima H, Kitami M, Matsushita H, Furukawa E, Narushima D, Nagai M, Taniguchi H, Motoi N, Sekine S, Maeshima A, Mori T, Watanabe R, Yoshida M, Yoshida A, Yoshida H, Satomi K, Sukeda A, Hashimoto T, Shimizu T, Iwasa S, Yonemori K, Kato K, Morizane C, Ogawa C, Tanabe N, Sugano K, Hiraoka N, Tamura K, Yoshida T, Fujiwara Y, Ochiai A, Yamamoto N, Kohno T.

Cancer Sci. 2019 Apr;110(4):1480-1490. doi: 10.1111/cas.13969. Epub 2019 Apr 2.

6.

Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population.

Noda-Narita S, Shimomura A, Kawachi A, Sumiyoshi-Okuma H, Sudo K, Shimoi T, Noguchi E, Yonemori K, Shimizu C, Fujiwara Y, Tamura K.

Breast Cancer. 2019 Feb 8. doi: 10.1007/s12282-019-00949-4. [Epub ahead of print]

PMID:
30737616
7.

The Incidence of Nonmalignant Diseases among Patients with Suspected Carcinoma of Unknown Primary Site.

Sato J, Shimoi T, Shimomura A, Noguchi E, Kodaira M, Yunokawa M, Yonemori K, Shimizu C, Fujiwara Y, Yoshida M, Tamura K.

Intern Med. 2019 May 15;58(10):1423-1428. doi: 10.2169/internalmedicine.1118-18. Epub 2019 Feb 1.

8.

Eradication therapy for Helicobacter pylori infection improves nutrition status in Japanese hemodialysis patients: a pilot study.

Ichikawa H, Sugimoto M, Sakao Y, Sahara S, Ohashi N, Sano K, Tadokoro S, Azekura H, Shimomura A, Yamashita F, Sugiyama D, Fukuta K, Furuta T, Kato A, Sugimoto K, Yasuda H.

J Clin Biochem Nutr. 2019 Jan;64(1):91-95. doi: 10.3164/jcbn.18-61. Epub 2018 Oct 2.

9.

A phase I/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes.

Yonemori K, Shimomura A, Yasojima H, Masuda N, Aogi K, Takahashi M, Naito Y, Shimizu S, Nakamura R, Hashimoto J, Yamamoto H, Hirakawa A, Michimae H, Hamada A, Yoshida T, Sukigara T, Tamura K, Fujiwara Y.

Eur J Cancer. 2019 Mar;109:84-91. doi: 10.1016/j.ejca.2018.11.014. Epub 2019 Jan 28.

PMID:
30703739
10.

First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors.

Shimomura A, Yamamoto N, Kondo S, Fujiwara Y, Suzuki S, Yanagitani N, Horiike A, Kitazono S, Ohyanagi F, Doi T, Kuboki Y, Kawazoe A, Shitara K, Ohno I, Banerji U, Sundar R, Ohkubo S, Calleja EM, Nishio M.

Mol Cancer Ther. 2019 Mar;18(3):531-540. doi: 10.1158/1535-7163.MCT-18-0831. Epub 2019 Jan 24.

PMID:
30679388
11.

A quality assurance for respiratory gated proton irradiation with range modulation wheel.

Yasui K, Shimomura A, Toshito T, Tanaka K, Ueki K, Muramatsu R, Katsurada M, Hayashi N, Ogino H.

J Appl Clin Med Phys. 2019 Jan;20(1):258-264. doi: 10.1002/acm2.12526. Epub 2018 Dec 30.

12.

Serum miRNA-based Prediction of Axillary Lymph Node Metastasis in Breast Cancer.

Shiino S, Matsuzaki J, Shimomura A, Kawauchi J, Takizawa S, Sakamoto H, Aoki Y, Yoshida M, Tamura K, Kato K, Kinoshita T, Kitagawa Y, Ochiya T.

Clin Cancer Res. 2019 Mar 15;25(6):1817-1827. doi: 10.1158/1078-0432.CCR-18-1414. Epub 2018 Nov 27.

PMID:
30482779
13.

Analysis of interference fringes based on three circularly polarized beams targeted for birefringence distribution measurements.

Shimomura A, Fukuda T, Emoto A.

Appl Opt. 2018 Sep 1;57(25):7318-7324. doi: 10.1364/AO.57.007318.

PMID:
30182994
14.

<Editors' Choice> Practice management for elderly patients with breast cancer; Findings from a survey by the Japan Breast Cancer Study Group.

Sawaki M, Tamura K, Shimomura A, Taki Y, Nagashima F, Iwata H.

Nagoya J Med Sci. 2018 May;80(2):217-226. doi: 10.18999/nagjms.80.2.217.

15.

PIK3CA mutation profiling in patients with breast cancer, using a highly sensitive detection system.

Shimoi T, Hamada A, Yamagishi M, Hirai M, Yoshida M, Nishikawa T, Sudo K, Shimomura A, Noguchi E, Yunokawa M, Yonemori K, Shimizu C, Kinoshita T, Fukuda T, Fujiwara Y, Tamura K.

Cancer Sci. 2018 Aug;109(8):2558-2566. doi: 10.1111/cas.13696. Epub 2018 Jul 28.

16.

Efficacy of capecitabine in patients with locally advanced or metastatic breast cancer with or without prior treatment with fluoropyrimidine: a retrospective study.

Iizumi S, Shimomura A, Shimoi T, Sudo K, Noguchi E, Yonemori K, Shimizu C, Fujiwara Y, Tamura K.

Cancer Chemother Pharmacol. 2018 Aug;82(2):275-283. doi: 10.1007/s00280-018-3617-5. Epub 2018 Jun 5.

17.

High and low estimated glomerular filtration rates are associated with adverse outcomes in patients undergoing surgery for gastrointestinal malignancies.

Ui T, Obi Y, Shimomura A, Lefor AK, Fazl Alizadeh R, Said H, Nguyen NT, Stamos MJ, Kalantar-Zadeh K, Sata N, Ichii H.

Nephrol Dial Transplant. 2019 May 1;34(5):810-818. doi: 10.1093/ndt/gfy108.

PMID:
29718365
18.

Protein carbamylation exacerbates vascular calcification.

Mori D, Matsui I, Shimomura A, Hashimoto N, Matsumoto A, Shimada K, Yamaguchi S, Oka T, Kubota K, Yonemoto S, Sakaguchi Y, Takahashi A, Shintani Y, Takashima S, Takabatake Y, Hamano T, Isaka Y.

Kidney Int. 2018 Jul;94(1):72-90. doi: 10.1016/j.kint.2018.01.033. Epub 2018 Apr 30.

PMID:
29716796
19.

Relevance of the hippocampal endoplasmic reticulum stress response in a mouse model of chronic kidney disease.

Kosuge Y, Osada N, Shimomura A, Miyagishi H, Wada T, Ishige K, Shimba S, Ito Y.

Neurosci Lett. 2018 Jun 11;677:26-31. doi: 10.1016/j.neulet.2018.04.021. Epub 2018 Apr 20.

PMID:
29680250
20.

Efficacy and Safety of Pazopanib for Recurrent or Metastatic Solitary Fibrous Tumor.

Ebata T, Shimoi T, Bun S, Miyake M, Yoshida A, Shimomura A, Noguchi E, Yonemori K, Shimizu C, Fujiwara Y, Narita Y, Tamura K.

Oncology. 2018;94(6):340-344. doi: 10.1159/000486623. Epub 2018 Apr 3.

PMID:
29614488
21.

Phase I study of taselisib in Japanese patients with advanced solid tumors or hormone receptor-positive advanced breast cancer.

Tamura K, Kodaira M, Shimizu C, Yonemori K, Yunokawa M, Shimomura A, Kobayashi T, Nakano K, Tomomatsu J, Ito Y, Tanaka J, Kuriki H, Gu Z, Takahashi S.

Cancer Sci. 2018 May;109(5):1592-1601. doi: 10.1111/cas.13561. Epub 2018 Mar 31.

22.

Gene aberration profile of tumors of adolescent and young adult females.

Kanke Y, Shimomura A, Saito M, Honda T, Shiraishi K, Shimada Y, Watanabe R, Yoshida H, Yoshida M, Shimizu C, Takahashi K, Totsuka H, Ogiwara H, Hirose S, Kono K, Tamura K, Okamoto A, Kinoshita T, Kato T, Kohno T.

Oncotarget. 2017 Dec 29;9(5):6228-6237. doi: 10.18632/oncotarget.23765. eCollection 2018 Jan 19.

23.

LATS2 promoter hypermethylation and its effect on gene expression in human breast cancer.

Matsui S, Kagara N, Mishima C, Naoi Y, Shimoda M, Shimomura A, Shimazu K, Kim SJ, Noguchi S.

Oncol Lett. 2018 Feb;15(2):2595-2603. doi: 10.3892/ol.2017.7535. Epub 2017 Dec 6.

24.

Prognostic impact of presumed breast or ovarian cancer among patients with unfavorable-subset cancer of unknown primary site.

Kodaira M, Yonemori K, Shimoi T, Yoshida A, Yoshida M, Kitano A, Shimomura A, Yunokawa M, Shimizu C, Takiguchi Y, Fujiwara Y, Tamura K.

BMC Cancer. 2018 Feb 13;18(1):176. doi: 10.1186/s12885-018-4092-4.

25.

[Local Control of Advanced Breast Cancer with Giant Ulcer].

Inoue T, Shimomura A, Sugimoto T, Wakamiya S, Chou U, Fujiwara A, Uchikoshi F, Watanabe T, Kitamura N.

Gan To Kagaku Ryoho. 2017 Nov;44(12):1062-1064. Japanese.

PMID:
29394534
26.

Endoglin (CD105) and SMAD4 regulate spheroid formation and the suppression of the invasive ability of human pancreatic cancer cells.

Kokaji E, Shimomura A, Minamisaka T, Nakajima T, Miwa S, Hatta H, Nishida T, Kiya C, Imura J.

Int J Oncol. 2018 Mar;52(3):892-900. doi: 10.3892/ijo.2018.4262. Epub 2018 Feb 1.

PMID:
29393426
27.

Symptom management: the utility of regional cooling for hand-foot syndrome induced by pegylated liposomal doxorubicin in ovarian cancer.

Bun S, Yunokawa M, Tamaki Y, Shimomura A, Shimoi T, Kodaira M, Shimizu C, Yonemori K, Fujiwara Y, Makino Y, Terakado H, Tamura K.

Support Care Cancer. 2018 Jul;26(7):2161-2166. doi: 10.1007/s00520-018-4054-z. Epub 2018 Jan 25.

PMID:
29372396
28.

The histone demethylase LSD1 regulates inner ear progenitor differentiation through interactions with Pax2 and the NuRD repressor complex.

Patel D, Shimomura A, Majumdar S, Holley MC, Hashino E.

PLoS One. 2018 Jan 25;13(1):e0191689. doi: 10.1371/journal.pone.0191689. eCollection 2018.

29.

TERT promoter hotspot mutations in breast cancer.

Shimoi T, Yoshida M, Kitamura Y, Yoshino T, Kawachi A, Shimomura A, Noguchi E, Yunokawa M, Yonemori K, Shimizu C, Kinoshita T, Ichimura K, Fukuda T, Fujiwara Y, Tamura K.

Breast Cancer. 2018 May;25(3):292-296. doi: 10.1007/s12282-017-0825-5. Epub 2017 Dec 8.

30.

New splicing variants of mitochondrial Rho GTPase-1 (Miro1) transport peroxisomes.

Okumoto K, Ono T, Toyama R, Shimomura A, Nagata A, Fujiki Y.

J Cell Biol. 2018 Feb 5;217(2):619-633. doi: 10.1083/jcb.201708122. Epub 2017 Dec 8.

31.

Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study.

Iizumi S, Shimoi T, Tsushita N, Bun S, Shimomura A, Noguchi E, Kodaira M, Yunokawa M, Yonemori K, Shimizu C, Fujiwara Y, Tamura K.

BMC Cancer. 2017 Dec 4;17(1):819. doi: 10.1186/s12885-017-3846-8.

32.

Evaluation of dosimetric advantages of using patient-specific aperture system with intensity-modulated proton therapy for the shallow depth tumor.

Yasui K, Toshito T, Omachi C, Hayashi K, Tanaka K, Asai K, Shimomura A, Muramatsu R, Hayashi N.

J Appl Clin Med Phys. 2018 Jan;19(1):132-137. doi: 10.1002/acm2.12231. Epub 2017 Nov 27.

33.

A case of heavily pretreated metastatic cardiac angiosarcoma treated successfully using eribulin.

Inagaki C, Shimoi T, Okuma H, Kitano A, Shimomura A, Noguchi E, Kodaira M, Yunokawa M, Yonemori K, Shimizu C, Yoshida A, Fujiwara Y, Tamura K.

Anticancer Drugs. 2018 Jan;29(1):97-101. doi: 10.1097/CAD.0000000000000558.

PMID:
29176397
34.

The Prognostic Impact of the Pathological Response to Neoadjuvant Dose-Dense Therapy for Ovarian Carcinoma.

Ebata T, Yunokawa M, Yoshida H, Bun S, Shimoi T, Shimomura A, Kodaira M, Yonemori K, Shimizu C, Fujiwara Y, Kato T, Tamura K.

Int J Gynecol Cancer. 2017 Nov;27(9):1850-1855. doi: 10.1097/IGC.0000000000001107.

PMID:
29040183
35.

Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study.

Doi T, Shitara K, Naito Y, Shimomura A, Fujiwara Y, Yonemori K, Shimizu C, Shimoi T, Kuboki Y, Matsubara N, Kitano A, Jikoh T, Lee C, Fujisaki Y, Ogitani Y, Yver A, Tamura K.

Lancet Oncol. 2017 Nov;18(11):1512-1522. doi: 10.1016/S1470-2045(17)30604-6. Epub 2017 Oct 13.

PMID:
29037983
36.

Prolonged Hypocalcemia Following a Single Dose of Denosumab for Diffuse Bone Metastasis of Gastric Cancer after Total Gastrectomy.

Iizumi S, Shimoi T, Nishikawa T, Kitano A, Sasada S, Shimomura A, Noguchi E, Yunokawa M, Yonemori K, Shimizu C, Fujiwara Y, Tamura K.

Intern Med. 2017 Nov 1;56(21):2879-2882. doi: 10.2169/internalmedicine.8908-17. Epub 2017 Sep 25.

37.

Durable complete response in HER2-positive breast cancer: a multicenter retrospective analysis.

Niikura N, Shimomura A, Fukatsu Y, Sawaki M, Ogiya R, Yasojima H, Fujisawa T, Yamamoto M, Tsuneizumi M, Kitani A, Watanabe J, Matsui A, Takahashi Y, Takashima S, Shien T, Tamura K, Saji S, Masuda N, Tokuda Y, Iwata H.

Breast Cancer Res Treat. 2018 Jan;167(1):81-87. doi: 10.1007/s10549-017-4489-9. Epub 2017 Sep 11.

PMID:
28895005
38.

Visualization of HER2-specific breast cancer intratumoral heterogeneity using 64Cu-DOTA-trastuzumab PET.

Sasada S, Kurihara H, Kinoshita T, Yoshida M, Honda N, Shimoi T, Shimomura A, Yonemori K, Shimizu C, Hamada A, Kanayama Y, Watanabe Y, Fujiwara Y, Tamura K.

Eur J Nucl Med Mol Imaging. 2017 Nov;44(12):2146-2147. doi: 10.1007/s00259-017-3781-6. Epub 2017 Aug 3. No abstract available.

PMID:
28770275
39.

Identification of sentinel lymph nodes by contrast-enhanced ultrasonography with Sonazoid in patients with breast cancer: a feasibility study in three hospitals.

Shimazu K, Ito T, Uji K, Miyake T, Aono T, Motomura K, Naoi Y, Shimomura A, Shimoda M, Kagara N, Kim SJ, Noguchi S.

Cancer Med. 2017 Aug;6(8):1915-1922. doi: 10.1002/cam4.1142. Epub 2017 Aug 1.

40.

Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancer.

Kitano A, Ono M, Yoshida M, Noguchi E, Shimomura A, Shimoi T, Kodaira M, Yunokawa M, Yonemori K, Shimizu C, Kinoshita T, Fujiwara Y, Tsuda H, Tamura K.

ESMO Open. 2017 May 2;2(2):e000150. doi: 10.1136/esmoopen-2016-000150. eCollection 2017.

41.

Association of pre-operative estimated GFR on post-operative pulmonary complications in laparoscopic surgeries.

Shimomura A, Obi Y, Fazl Alizadeh R, Li S, Nguyen NT, Stamos MJ, Kalantar-Zadeh K, Ichii H.

Sci Rep. 2017 Jul 26;7(1):6504. doi: 10.1038/s41598-017-06842-4.

42.

Feasibility of olanzapine, multi acting receptor targeted antipsychotic agent, for the prevention of emesis caused by continuous cisplatin- or ifosfamide-based chemotherapy.

Bun S, Yonemori K, Akagi T, Noguchi E, Shimoi T, Shimomura A, Yunokawa M, Shimizu C, Fujiwara Y, Makino Y, Hayashi Y, Tamura K.

Invest New Drugs. 2018 Feb;36(1):151-155. doi: 10.1007/s10637-017-0487-3. Epub 2017 Jul 21.

PMID:
28733700
43.

A small-molecule inhibitor of SMAD3 attenuates resistance to anti-HER2 drugs in HER2-positive breast cancer cells.

Chihara Y, Shimoda M, Hori A, Ohara A, Naoi Y, Ikeda JI, Kagara N, Tanei T, Shimomura A, Shimazu K, Kim SJ, Noguchi S.

Breast Cancer Res Treat. 2017 Nov;166(1):55-68. doi: 10.1007/s10549-017-4382-6. Epub 2017 Jul 12.

PMID:
28702892
44.
45.

Risk of Postoperative Venous Thromboembolism Among Pregnant Women.

Suematsu Y, Obi Y, Shimomura A, Alizadeh RF, Vaziri ND, Nguyen NT, Stamos MJ, Ichii H.

Am J Cardiol. 2017 Aug 1;120(3):479-483. doi: 10.1016/j.amjcard.2017.04.053. Epub 2017 May 11.

46.

New predictive model for acute gastrointestinal bleeding in patients taking oral anticoagulants: A cohort study.

Shimomura A, Nagata N, Shimbo T, Sakurai T, Moriyasu S, Okubo H, Watanabe K, Yokoi C, Akiyama J, Uemura N.

J Gastroenterol Hepatol. 2018 Jan;33(1):164-171. doi: 10.1111/jgh.13830.

PMID:
28544091
47.

Allred score is a promising predictor of prognosis and medroxyprogesterone acetate efficacy in patients with endometrial cancer.

Yunokawa M, Yoshida H, Watanabe R, Noguchi E, Shimomura A, Shimoi T, Yonemori K, Shimizu C, Fujiwara Y, Tamura K.

Cancer Chemother Pharmacol. 2017 Jul;80(1):127-134. doi: 10.1007/s00280-017-3342-5. Epub 2017 May 24.

PMID:
28540420
48.

64Cu-DOTA-trastuzumab PET imaging for HER2-specific primary lesions of breast cancer.

Sasada S, Kurihara H, Kinoshita T, Yoshida M, Honda N, Shimoi T, Shimomura A, Yunokawa M, Yonemori K, Shimizu C, Hamada A, Kanayama Y, Watanabe Y, Fujiwara Y, Tamura K.

Ann Oncol. 2017 Aug 1;28(8):2028-2029. doi: 10.1093/annonc/mdx227. No abstract available.

PMID:
28505219
49.

Paclitaxel-induced sensory peripheral neuropathy is associated with an ABCB1 single nucleotide polymorphism and older age in Japanese.

Tanabe Y, Shimizu C, Hamada A, Hashimoto K, Ikeda K, Nishizawa D, Hasegawa J, Shimomura A, Ozaki Y, Tamura N, Yamamoto H, Yunokawa M, Yonemori K, Takano T, Kawabata H, Tamura K, Fujiwara Y.

Cancer Chemother Pharmacol. 2017 Jun;79(6):1179-1186. doi: 10.1007/s00280-017-3314-9. Epub 2017 Apr 26.

PMID:
28447211
50.

Do all patients in the phase I oncology trials need to be hospitalized? Domestic but outstanding issues for globalization of drug development in Japan.

Shimomura A, Kondo S, Kobayashi N, Iwasa S, Kitano S, Tamura K, Fujiwara Y, Yamamoto N.

Int J Clin Oncol. 2017 Aug;22(4):780-785. doi: 10.1007/s10147-017-1108-z. Epub 2017 Mar 14.

Supplemental Content

Loading ...
Support Center